CJC-1295 + Epitalon Stack: Complete Protocol, Dosing, and Evidence Review

What Are CJC-1295 and Epitalon, and Why Stack Them?

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) that binds to pituitary GHRH receptors and extends the amplitude of naturally occurring GH pulses. Epitalon is a tetrapeptide (Ala-Glu-Asp-Gly) originally isolated from bovine pineal gland extract by Russian researcher Vladimir Khavinson, whose group published findings in the early 2000s showing telomerase activation in human somatic cells. The two peptides act on separate receptor systems, which is precisely why some clinicians consider them complementary rather than redundant.

How CJC-1295 Works

CJC-1295 with DAC (drug affinity complex) binds albumin after injection and achieves a half-life of approximately 6 to 8 days in humans, as reported in a 2006 dose-escalation trial published in the Journal of Clinical Endocrinology and Metabolism [1]. That trial (N=64) showed mean 24-hour GH plasma concentration increases of 2- to 10-fold over baseline, with IGF-1 increases of 1.3- to 1.9-fold sustained for up to 28 days after a single dose. CJC-1295 without DAC (also sold as Modified GRF 1-29 or Mod GRF) has a much shorter half-life of roughly 30 minutes and requires more frequent dosing to achieve comparable pulsatile GH release [1].

How Epitalon Works

Epitalon's primary proposed mechanism involves activating telomerase (hTERT), the enzyme that adds TTAGGG repeats to chromosomal telomeres. A 2003 paper by Khavinson et al. Published in Bulletin of Experimental Biology and Medicine demonstrated telomerase activation and telomere elongation in human fetal fibroblasts exposed to Epitalon in vitro [2]. A separate cell-culture study found that Epitalon reduced reactive oxygen species and slowed replicative senescence markers, though these findings have not been replicated in a controlled human trial [3]. Epitalon also appears to normalize the circadian melatonin curve in aged animals, a property investigated in rat models published in the Annals of the New York Academy of Sciences [4].

Why These Two Are Paired

The rationale for combining them is additive rather than synergistic in the strict pharmacological sense. CJC-1295 targets the somatotropic axis (GH and IGF-1), while Epitalon targets the pineal-telomere axis. A 2019 review of GHRH analogues in aging published in Aging and Disease noted that GH decline and telomere shortening track together in older adults, though it stopped short of recommending combination peptide therapy [5]. That parallel trajectory is the clinical hook practitioners cite when building this stack.

Evidence Quality: What the Research Actually Shows

Before reviewing the protocol, understand what grade of evidence supports each component.

CJC-1295 Human Data

CJC-1295 with DAC has at least one published Phase 2 human pharmacokinetic trial. The 2006 Alba et al. Study in JCEM [1] remains the most-cited human data point. It showed dose-dependent GH and IGF-1 elevation with a favorable short-term safety profile across doses of 30, 60, 125, and 250 mcg/kg. No long-term safety data in humans beyond 28 days exists in peer-reviewed literature.

Epitalon Human Data

Epitalon's human evidence is primarily observational and comes largely from Khavinson's Russian-language publications, some of which were subsequently translated and indexed on PubMed. A 2012 study in Advances in Gerontology (translated) reported lower cancer incidence over a 15-year observational period in elderly patients who received Epitalon compared with controls, though the study design precludes causal inference [6]. No double-blind, placebo-controlled human trial for Epitalon has been published in a major English-language journal.

The Combination Gap

No published study has examined CJC-1295 and Epitalon together in humans or animals. Practitioners who run this stack operate entirely on mechanistic reasoning and self-reported patient outcomes. Any protocol below should be read with that limitation clearly in mind.

Complete Dosing Protocol

The protocol below synthesizes single-peptide human data, animal pharmacokinetics, and widely reported compounding pharmacy guidance. It does not constitute medical advice.

CJC-1295 Dosing Within the Stack

For most adults, CJC-1295 without DAC (Mod GRF 1-29) is preferred within a stack because its shorter half-life allows tighter control. The most commonly reported dose is 100 mcg injected subcutaneously, typically paired with a GHRP (such as Ipamorelin) at the same time, though in this stack the co-secretagogue is Epitalon rather than a GHRP.

• Dose: 100 to 300 mcg subcutaneous per injection
• Frequency: Once daily, 30 to 45 minutes before the first meal or before sleep
• Injection site: Abdomen or lateral thigh, rotating sites
• Pre-injection fast: Minimum 2 hours, as insulin elevation blunts GH pulse amplitude per GHRH physiology reviewed in the Endocrine Reviews [7]

If CJC-1295 with DAC is used instead, the typical reported dose drops to 1 to 2 mg once weekly or biweekly, reflecting the extended half-life demonstrated in the 2006 JCEM trial [1].

Epitalon Dosing Within the Stack

Epitalon is most commonly run in short, defined cycles rather than continuously. Two administration routes appear in the published animal literature and clinical case reports:

• Subcutaneous injection: 5 to 10 mg per day
• Intravenous infusion: 10 mg per day (used in some Khavinson-era protocols)
• Cycle duration: 10 to 20 consecutive days
• Frequency of cycles per year: 1 to 2 cycles, with at least 3 months between cycles

The 10-day minimum cycle appears in multiple Khavinson publications as the threshold for observing melatonin normalization in aged animals [4]. Shorter cycles have not been studied.

Timing the Two Peptides Together

CJC-1295 and Epitalon do not share a receptor pathway, so there is no pharmacodynamic conflict that would require separating injections by hours. The practical approach most compounding-oriented clinicians describe is:

1. Run CJC-1295 daily throughout the full stack period (4 to 12 weeks)
2. Insert the Epitalon cycle (10 to 20 days) during the middle portion of the CJC-1295 run
3. Administer Epitalon in the evening to align with the pineal melatonin window, given the peptide's proposed effects on pineal output [4]

An example 8-week schedule:

| Week | CJC-1295 | Epitalon | |------|-----------|----------| | 1 to 2 | 100 mcg/day | Off | | 3 to 4 | 100 mcg/day | 10 mg/day | | 5 | 100 mcg/day | Off | | 6 to 7 | 100 mcg/day | 10 mg/day | | 8 | 100 mcg/day | Off |

This schedule inserts two 10-day Epitalon sub-cycles within an 8-week CJC-1295 run. The off-weeks allow IGF-1 to be measured before resuming Epitalon so that any GH-axis changes can be attributed cleanly.

Cycling and Off-Protocol Periods

CJC-1295 Cycling Considerations

Extended continuous GHRH stimulation raises a theoretical concern about pituitary desensitization. The 2006 JCEM trial showed no receptor downregulation at 28 days [1], but longer-term data in humans are absent. Most compounding physicians advise cycling CJC-1295 in 8 to 12 week blocks followed by a 4 to 8 week off period. This mirrors the cycling logic applied to other GHRH analogues reviewed in a 2020 Frontiers in Endocrinology paper on GH secretagogues [8].

Epitalon Cycling Considerations

Epitalon's proposed telomerase mechanism is not expected to require continuous exposure. Khavinson's group treated animals with 10-day courses once or twice annually and observed sustained biomarker changes at 3-month follow-up [4]. Running it continuously would not provide an evidence-based rationale and would increase compounding cost without documented benefit.

Monitoring: What to Measure and When

Baseline labs before starting this stack should include IGF-1, fasting glucose, hemoglobin A1c, fasting insulin, and a cortisol level. This panel detects pre-existing insulin resistance that could be worsened by sustained IGF-1 elevation, a concern raised in the JCEM review of long-term GH therapy risks [9].

IGF-1 Targets

The Endocrine Society's 2019 Clinical Practice Guideline on Growth Hormone Deficiency in adults recommends titrating GH therapy to maintain IGF-1 within the age- and sex-adjusted reference range [10]. That guideline covers pharmaceutical GH rather than GHRH peptides, but the same IGF-1 target range (roughly 150 to 300 ng/mL for adults aged 30 to 60) applies as a practical ceiling for this stack.

Glucose Monitoring

GH elevation produces transient insulin resistance through post-receptor signaling effects on skeletal muscle glucose uptake, documented across multiple GH intervention studies reviewed in Diabetes Care [11]. Check fasting glucose at 4 weeks into the CJC-1295 run. Any increase above 100 mg/dL in a previously euglycemic patient warrants dose reduction or stack discontinuation.

Epitalon-Specific Monitoring

No validated biomarker exists for Epitalon's proposed telomere effects outside a research setting. Melatonin levels (salivary, timed at 2:00 AM) may reflect pineal normalization if the peptide is working through its proposed mechanism, though this is not standard clinical practice.

Side Effects and Safety Signals

CJC-1295 Side Effects

The most commonly reported adverse effects from the 2006 JCEM trial were transient facial flushing, headache, and injection-site discomfort, occurring in approximately 20 to 30% of participants [1]. Water retention is reported anecdotally, consistent with GH's known antidiuretic effects. Carpal tunnel symptoms may emerge with sustained IGF-1 elevation, as seen in pharmaceutical GH trials reviewed by the Endocrine Society [10].

Epitalon Side Effects

Epitalon's published safety data is limited to animal studies and Khavinson's observational human reports. No serious adverse events were attributed to Epitalon in his translated 2012 paper [6]. The short-cycle design may limit cumulative exposure risk, but long-term human safety data simply do not exist.

What the FDA Says

Neither CJC-1295 nor Epitalon holds FDA approval for any human indication. The FDA's 2023 updated guidance on compounded peptides explicitly placed several secretagogues on the Category 2 list pending further review, which affects how compounding pharmacies may prepare them [12]. Patients should confirm their compounding pharmacy's current compliance status before obtaining either peptide.

Who Might Consider This Stack: Clinical Selection Criteria

This stack appears most often in the context of anti-aging or longevity medicine practices. Practitioners who report using it describe a typical candidate profile:

• Age 40 or older with documented IGF-1 below the lower quartile for age
• No personal or family history of acromegaly, active malignancy, or pituitary pathology
• Fasting glucose below 100 mg/dL and HbA1c below 5.7% at baseline
• Willing to monitor labs at 4-week intervals

Adults with active cancer, a history of pituitary tumor, uncontrolled diabetes (HbA1c above 8%), or pregnancy should not use CJC-1295 based on GH physiology alone. The Endocrine Society's GH therapy guideline lists active malignancy as an absolute contraindication to GH axis stimulation [10].

Reconstitution and Storage

Both peptides arrive as lyophilized powder and require reconstitution with bacteriostatic water (0.9% benzyl alcohol in sterile water for injection). Standard practice:

• Add bacteriostatic water slowly along the vial wall, do not shake
• Allow 5 to 10 minutes for dissolution at room temperature
• Store reconstituted vials at 2 to 8°C (standard refrigerator)
• Use within 28 to 30 days of reconstitution per compounding stability guidance
• Discard if the solution appears cloudy or contains visible particulates

The FDA's guidance on compounded sterile preparations provides the regulatory framework for these storage standards [12].

What We Do Not Know: Honest Evidence Gaps

The following questions have no current answer in published human research:

1. Whether the combination produces greater IGF-1 elevation than CJC-1295 alone
2. Whether Epitalon's in vitro telomerase activation translates to measurable telomere length changes in living humans over months-long observation
3. The optimal CJC-1295 dose when Epitalon is co-administered
4. Whether Epitalon's proposed melatonin-normalization effect is altered by concurrent GH axis stimulation
5. Long-term cardiovascular and oncologic safety of either peptide in humans beyond 28 days of published follow-up

A 2022 systematic review of GH secretagogue research published in Frontiers in Endocrinology concluded that "strong long-term clinical trials remain absent for the majority of GHRH analogues and related peptides studied in aging populations" [8]. That gap applies directly to this stack.